Richard Pazdur, MD, from the FDA’s Center for Drug Evaluation and Research, describes the benefits of a Breakthrough Therapy Designation.
Richard Pazdur, MD, director of the Office of Hematology and Oncology Products in FDA’s Center for Drug Evaluation and Research, describes the benefits of a Breakthrough Therapy Designation.
There have been several drugs in the past that would have benefited from the increased interaction between sponsors and the FDA from a Breakthrough Therapy Designation, Pazdur notes.
The concept behind a Breakthrough Therapy Designation is that the FDA will be involved with the sponsor on an ongoing basis to address clinical application, manufacturing issues, clinical pharmacology issues, and preclinical issues in a timely fashion.
<<<